■白癜风是一种慢性,自身免疫性疾病的特征是由炎症介导的黑素细胞降解引起的皮肤色素脱失。由于白癜风的慢性性质,白癜风的治疗具有挑战性。1.5%的鲁索替尼乳膏最近被食品和药物管理局(FDA)批准作为Janus激酶1和2抑制剂用于12岁及以上的非节段白癜风。
■本综述的目的是描述鲁索利替尼在治疗非节段白癜风中的作用。我们用搜索词非节段白癜风搜索PubMed,Jak抑制剂,和鲁索替尼.Clinicaltrials.gov用于确定临床试验数据,包括疗效,药效学,药代动力学,安全,和耐受性。
■在II期和III期(TRuE-V1和TRuE-V2)试验中,ruxolitinib乳膏1.5%改善了色素沉着,副作用最小。外用鲁索替尼是一种急需的新型白癜风治疗选择。如果不能克服局部治疗依从性差的障碍,现实生活中的疗效可能与临床试验中的疗效不符。
UNASSIGNED: Vitiligo is a chronic, autoimmune condition characterized by skin depigmentation caused by inflammatory-mediated melanocyte degradation. Treatment of vitiligo is challenging due to the chronic nature of the condition. Ruxolitinib cream 1.5% was recently approved by the Food and Drug Administration (FDA) as a Janus kinase 1 and 2 inhibitor for use in nonsegmental vitiligo for those 12 years and older.
UNASSIGNED: The purpose of this review is to describe the role of ruxolitinib in treating nonsegmental vitiligo.We searched PubMed using search terms nonsegmental vitiligo, jak inhibitor, and ruxolitinib. Clinicaltrials.gov was used to identify clinical trial data including efficacy, pharmacodynamics, pharmacokinetics, safety, and tolerability.
UNASSIGNED: In both phase II and phase III (TRuE-V1 and TRuE-V2) trials, ruxolitinib cream 1.5% improved repigmentation with minimal adverse effects. Topical ruxolitinib is a much needed new vitiligo treatment option. Real life efficacy may not match that seen in clinical trials if the hurdle of poor adherence to topical treatment is not surmounted.